Skip to main content

Table 1 Baseline* characteristics of RA patients in RISE EHR and MarketScan data according to the testing status for rheumatoid factor and anti-CCP antibody

From: Use of ICD-10 diagnosis codes to identify seropositive and seronegative rheumatoid arthritis when lab results are not available

  RISE EHR (n = 134,406) MarketScan (n = 78,787)
Not tested Tested, without results** Tested, with results** SMD Not tested Tested, without results** Tested, with results ** SMD
N 72,432 8710 53,264   46,676 29,925 2186  
Age 62.5 (13.5) 61.3 (14.0) 60.7 (14.0) 0.0877 56.82 (12.70) 52.13 (11.54) 54.04 (12.19) 0.2572
Female 55,930 (77.2) 6758 (77.6) 41,365 (77.7) 0.0225 36,376 (77.9) 23,485 (78.5) 1735 (79.4) 0.0234
Charlson Comorbidity Index     0.0363     0.0973
 1–2 68,170 (94.1) 8118 (93.2) 46,948 (93.2)   31,615 (67.7) 20,410 (68.2) 1366 (62.5)  
 3–4 3938 (5.4) 561 (6.4) 3334 (93.2)   9351 (20.0) 6330 (21.2) 517 (23.7)  
 ≥ 5 324 (0.4) 31 (0.4) 282 (0.5)   5710 (12.2) 3185 (10.6) 303 (13.9)  
Comorbidities***
 Cerebrovascular disease 556 (0.8) 54 (0.6) 375 (0.7) 0.0119 5081 (10.9) 2847 (9.5) 271 (12.4) 0.0616
 Congestive heart failure 364 (0.5) 47 (0.5) 258 (0.5) 0.0052 2951 (6.3) 1502 (5.0) 148 (6.8) 0.0496
 Constructive pulmonary disease 2612 (3.6) 332 (3.8) 1856 (3.5) 0.0116 13,155 (28.2) 9010 (30.1) 638 (29.2) 0.0282
 Diabetes without complication 3076 (4.2) 438 (5.0) 2961 (5.6) 0.0406 5777 (12.4) 4262 (14.2) 366 (16.7) 0.0827
 Diabetes with complication 289 (0.4) 28 (0.3) 260 (0.5) 0.0175 2774 (5.9) 1643 (5.5) 158 (7.2) 0.0475
 Malignancy 1302 (1.8) 173 (2.0) 954 (1.8) 0.0096 3837 (8.2) 2108 (7.0) 172 (7.9) 0.0295
 Myocardial infarction 67 (0.1) 7 (0.1) 47 (0.1) 0.0028 1559 (3.3) 748 (2.5) 61 (2.8) 0.0333
 Mild liver disease 957 (1.3) 163 (1.9) 1134 (2.1) 0.0415 4673 (10.0) 3762 (12.6) 327 (15.0) 0.1001
 Peptic ulcer disease 345 (0.5) 47 (0.5) 284 (0.5) 0.0059 406 (0.9) 262 (0.9) 26 (1.2) 0.0211
 Peripheral vascular disease 453 (0.6) 72 (0.8) 398 (0.7) 0.0158 1360 (2.9) 939 (3.1) 79 (3.6) 0.0263
 Stroke 234 (0.3) 18 (0.2) 151 (0.3) 0.0151 1479 (3.2) 819 (2.7) 85 (3.9) 0.043
Medication use, %
 Methotrexate 39,177 (54.1) 4567 (52.4) 29,128 (54.7) 0.0301 26,185 (56.1) 17,789 (59.4) 1371 (62.7) 0.09
 Other csDMARDS 28,950 (40.0) 3927 (45.1) 24,042 (45.1) 0.0698 19,894 (42.6) 14,915 (49.8) 996 (45.6) 0.0967
 TNFi biologics 18,151 (25.1) 1961 (22.5) 11,443 (21.5) 0.0565 19,030 (40.8) 8204 (27.4) 525 (24.0) 0.2421
 Non-TNFi biologics 6495 (9.0) 663 (7.6) 3662 (6.9) 0.0517 6593 (14.1) 2814 (9.4) 183 (8.4) 0.122
 Targeted synthetic DMARDs 2694 (3.7) 342 (3.9) 1638 (3.1) 0.0309 2048 (4.4) 983 (3.3) 48 (2.2) 0.0824
 NSAIDs 24,610 (34.0) 3273 (37.6) 20,631 (38.7) 0.0660 20,925 (44.8) 18,289 (61.1) 1332 (60.9) 0.2204
 Opioids 14,177 (19.6) 1799 (20.7) 11,123 (20.9) 0.0217 21,849 (46.8) 16,795 (56.1) 1197 (54.8) 0.1247
 Glucocorticoid use 26,889 (37.1) 3552 (40.8) 24,132 (45.3) 0.1111 34,034 (72.9) 25,335 (84.7) 1852 (84.7) 0.1947
Seropositive by RF and/or CCP, % N/A N/A 30,530 (57.3)   N/A N/A 1511 (69.1)  
M05 diagnosis code (rather than M06), % 46,084 (63.6) 4753 (54.6) 29,245 (54.9) 0.1233 25,728 (55.1) 15,584 (52.1) 1226 (56.1) 0.0536
  1. SMD standardized mean difference, SMDs > 0.10 are potentially important; DMARD disease-modifying anti-rheumatic drug; TNFi tumor necrosis factor inhibitor; NSAID non-steroidal anti-inflammatory drugs. Baseline refers to the date of the 2nd ICD-10 diagnosis code for RA
  2. **Tested with results means that the patient was tested for either or both RF and anti-CCP antibody (e.g., based on billing claims for the relevant lab tests) and had a valid lab result available; tested without results means that they were tested, but results were not available in the dataset; ***as measured in the Charlson Comorbidity Index